Real World Conversations About Real World Evidence

Real World Conversations About Real World Evidence

FDA Insights and Real-World Registry Success

Hosted by Navitas Life Sciences and Healthcare Innovation Catalysts (HIC)

About the series

Real-world data (RWD) and real-world evidence (RWE) are reshaping regulatory decisions, clinical development, and patient access. This expert-led conversation brings together perspectives on how the FDA is approaching RWE, and what it takes to build registries that truly deliver scientific and regulatory impact.

Key Insights You’ll Gain

FDA perspectives on the evolving role of RWE
Best practices for building and sustaining real-world registries
Case experiences on how RWE supports clinical and post-marketing studies
Practical strategies for aligning registry design with regulatory expectations

Meet the Experts

Yun Lu, PhD
SVP & Chief Science and Innovation Officer
Navitas Life Sciences

Benjamin C. Eloff, PhD
Head of Client Delivery & Quality
Healthcare Innovation Catalysts

Janel Shelton-DeMagnus
Director, Therapeutic Lead and Strategy
Navitas Life Sciences

Discover how evidence built on real-world data can move your science, strategy, and patients forward. Complete the form to watch the insightful discussion today.